Jupiter Wellness, Inc. (JUPW)

$OTRK 2 catalysts coming (Qtr Earnings Friday and Credit Suisse Conference Tuesday)
Outstanding 19.15M
Float 8.3M
Short Interest 29.71% ~ 33.16%
% Insiders own 55.72%
% Institutions own 30.80%
52 Week Range $8.46 - $99.89

All Analysts have this as a strong buy and heavily oversold with fair price value of $16-$22.

Smells like a squeeze 👏👏👏

Also in $IRNT $JUPW as well

New Release

JUPITER, FL / November 11, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a clinical stage company developing cannabinoid receptor agonists for the treatment of eczema, actinic keratosis, burns, and herpes cold sores, announced that it has received an official written response from a Type B pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) for JW-100, a topical drug the treatment of eczema.

The main purpose of the pre-IND meeting was to evaluate the drug development plan for JW-100.

Jupiter Wellness believes that the written response from the FDA supports the Company’s approach and its overall drug development strategy to enable the filing of an IND for its clinical studies on JW-100.

Dr. Glynn Wilson, Chief Scientific Officer of Jupiter Wellness, stated, “The pre-IND meeting written response marks an important milestone in the development of JW-100 for the treatment of eczema. We have obtained FDA concurrence and clear guidance on the proposed manufacturing, nonclinical pharmacology, and toxicology studies, and the Phase 1 clinical design.”

JW-100 met its primary endpoint in a recently completed Phase 1-equivalent international study in which Jupiter’s topical formulation cleared or reduced eczema following two weeks of use. These results suggest JW-100 may potentially prove superior to existing prescription drugs for the treatment of eczema in future clinical trials. The global eczema treatment market is valued at $10 billion and expected to grow at a CAGR of 13% from 2020-2025.

Top percent stock gainers for Tues. (GTE made it)
$BTBT
$ZETA
$MARPS
$JUPW
$GTE